Arrakis Inks First Partnership In RNA-Targeted Collaboration With Roche
Executive Summary
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.
You may also be interested in...
Roche Partnering Finds Upfront Fee Relief In Current Market
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.